Second, the clonal-formation assays showed that silencing MYBL2 promoted the cell proliferation inhibition by MK-1775 treatment (Fig. 5B, S4), and the MTT assays showed that the ED50s of MK-1775 were reduced about 50% with the knockdown of WEE1 in CRC cells (Fig. S5). This evidence concerns the gene MYBL2 and colorectal carcinoma.